| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 3,642.4 | 3,488.6 | 3,192.9 | 2,604.2 | 2,184.3 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 3,642.4 | 3,488.6 | 3,192.9 | 2,604.2 | 2,184.3 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 103.8 | 90.6 | 70.9 | 52.8 | 99.6 |
Total Income | 3,746.2 | 3,579.2 | 3,263.8 | 2,657 | 2,283.9 |
Total Expenditure | 2,600.6 | 2,485.3 | 2,258.5 | 1,838.8 | 1,512.5 |
PBIDT | 1,145.6 | 1,093.9 | 1,005.3 | 818.2 | 771.4 |
Interest | 53.1 | 47.2 | 45.2 | 24.1 | 27.7 |
PBDT | 1,092.5 | 1,046.7 | 960.1 | 794.1 | 743.7 |
Depreciation | 432.6 | 425.9 | 366.5 | 309.7 | 274.5 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 138.4 | 123 | 106.1 | 88.6 | 64.3 |
Deferred Tax | 25.3 | -12.2 | 23.1 | 0 | 0 |
Reported Profit After Tax | 496.2 | 510 | 464.4 | 395.8 | 404.9 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 496.2 | 510 | 464.4 | 395.8 | 404.9 |
Extra-ordinary Items | 24.06 | -8.9 | 0 | -25.08 | 30.2 |
Adjusted Profit After Extra-ordinary item | 472.14 | 518.9 | 464.4 | 420.88 | 374.7 |
EPS (Unit Curr.) | 12.35 | 12.71 | 11.59 | 9.94 | 10.18 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 12.5 | 12.5 | 12.5 | 10 | 0 |
Equity | 402.5 | 402 | 401.4 | 400.8 | 400 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 31.45 | 31.35 | 31.48 | 31.41 | 35.31 |
PBDTM(%) | 29.99 | 30 | 30.06 | 30.49 | 34.04 |
PATM(%) | 13.62 | 14.61 | 14.54 | 15.19 | 18.53 |
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
